ZLAB Zai Lab Ltd

Price (delayed)

$14.31

Market cap

$1.42B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.5

Enterprise value

$644.68M

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To ...

Highlights
The debt has contracted by 26% YoY and by 9% from the previous quarter
Zai Lab's revenue has increased by 24% YoY
The company's net income rose by 25% YoY but it fell by 11% QoQ
The EPS has grown by 24% YoY but it has contracted by 13% from the previous quarter
The quick ratio is down by 43% year-on-year and by 39% since the previous quarter
The equity has contracted by 24% YoY and by 10% from the previous quarter

Key stats

What are the main financial stats of ZLAB
Market
Shares outstanding
99.21M
Market cap
$1.42B
Enterprise value
$644.68M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.78
Price to sales (P/S)
5.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.42
Earnings
Revenue
$266.72M
EBIT
-$334.62M
EBITDA
-$316.88M
Free cash flow
-$191.38M
Per share
EPS
-$3.5
Free cash flow per share
-$1.98
Book value per share
$8.05
Revenue per share
$2.76
TBVPS
$10.55
Balance sheet
Total assets
$1.04B
Total liabilities
$240.18M
Debt
$15.15M
Equity
$796.12M
Working capital
$736.54M
Liquidity
Debt to equity
0.02
Current ratio
4.63
Quick ratio
4.29
Net debt/EBITDA
2.45
Margins
EBITDA margin
-118.8%
Gross margin
64.1%
Net margin
-125.5%
Operating margin
-134.8%
Efficiency
Return on assets
-30.7%
Return on equity
-37.1%
Return on invested capital
-273.4%
Return on capital employed
-40.2%
Return on sales
-125.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZLAB stock price

How has the Zai Lab stock price performed over time
Intraday
-4.66%
1 week
-7.8%
1 month
-26.77%
1 year
-60.03%
YTD
-47.64%
QTD
-10.67%

Financial performance

How have Zai Lab's revenue and profit performed over time
Revenue
$266.72M
Gross profit
$170.9M
Operating income
-$359.57M
Net income
-$334.62M
Gross margin
64.1%
Net margin
-125.5%
The net margin has grown by 39% YoY but it has contracted by 10% from the previous quarter
The company's operating margin rose by 28% YoY but it fell by 8% QoQ
The company's net income rose by 25% YoY but it fell by 11% QoQ
Zai Lab's revenue has increased by 24% YoY

Growth

What is Zai Lab's growth rate over time

Valuation

What is Zai Lab stock price valuation
P/E
N/A
P/B
1.78
P/S
5.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.42
The EPS has grown by 24% YoY but it has contracted by 13% from the previous quarter
The stock's P/B is 67% below its 5-year quarterly average of 5.7 and 40% below its last 4 quarters average of 3.1
The equity has contracted by 24% YoY and by 10% from the previous quarter
ZLAB's price to sales (P/S) is 95% lower than its 5-year quarterly average of 119.0 and 50% lower than its last 4 quarters average of 10.8
Zai Lab's revenue has increased by 24% YoY

Efficiency

How efficient is Zai Lab business performance
Zai Lab's return on invested capital has shrunk by 86% YoY and by 21% QoQ
The ROS has grown by 39% YoY but it has contracted by 10% from the previous quarter
ZLAB's ROE is down by 19% QoQ but it is up by 2.4% YoY
The ROA has contracted by 16% from the previous quarter but it has grown by 6% YoY

Dividends

What is ZLAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZLAB.

Financial health

How did Zai Lab financials performed over time
The company's total liabilities rose by 48% QoQ and by 38% YoY
The quick ratio is down by 43% year-on-year and by 39% since the previous quarter
The debt is 98% less than the equity
The debt has contracted by 26% YoY and by 9% from the previous quarter
The equity has contracted by 24% YoY and by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.